Skip to main content
Clinical Trials/NCT06106139
NCT06106139
Not yet recruiting
Phase 1

The Effectiveness of Ketogenic Diet in Preventing or Improving Thrombocytopenia in Cancer Patients Undergoing Chemotherapy: a Randomized Controlled Single Blind Study

Baoling Guo0 sites80 target enrollmentMay 12, 2024
ConditionsKetogenic Diet

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Ketogenic Diet
Sponsor
Baoling Guo
Enrollment
80
Primary Endpoint
thrombocytopenia
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

The main purpose of this study is to evaluate whether dietary intervention through ketogenic diet can prevent or improve chemotherapy related thrombocytopenia in cancer patients.

Detailed Description

In the study, 80 patients with malignant solid tumors undergoing chemotherapy were randomly assigned to the normal diet group, the strict ketogenic diet group, the circulating ketogenic diet group, and the autonomous ketogenic group. During the chemotherapy period, the corresponding dietary intervention was carried out, and the clinical data of patients before and after treatment were collected, including blood routine, blood ketone concentration, weight, blood sugar, blood lipids, adverse events, and changes in platelets before and after chemotherapy, Statistical analysis of data such as the change degree of platelets and the incidence of adverse events in each diet group before and after treatment was carried out to evaluate the impact of ketogenic diet on clinical indicators and adverse reactions of chemotherapy in cancer patients.

Registry
clinicaltrials.gov
Start Date
May 12, 2024
End Date
June 10, 2025
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Baoling Guo
Responsible Party
Sponsor Investigator
Principal Investigator

Baoling Guo

associate chief physician

Fujian Medical University

Eligibility Criteria

Inclusion Criteria

  • Between the ages of 18 and 90, regardless of gender
  • ECOG score ≤ 2 points
  • Received or expected to receive radiotherapy and chemotherapy during tumor activity
  • Body mass index 19-29
  • Conscious and autonomous eaters

Exclusion Criteria

  • Patients with basic diseases of diabetes
  • Complications such as severe liver and kidney dysfunction or digestive tract obstruction, inability to eat
  • Those who have a preference for food and have strict requirements for dietary taste
  • Disagree to sign informed consent
  • Those whose physical conditions are determined by the doctor to be impermissible

Outcomes

Primary Outcomes

thrombocytopenia

Time Frame: During radiotherapy and chemotherapy, approximately 3 months

Similar Trials